ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements
Avience Biomedicals Ltd reported revenue from operations of ₹31.1 Cr (+16.0% YoY) and net profit of ₹5.5 Cr (+22.2% YoY) for H1 FY27.
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.
Avience Biomedicals Limited has appointed M.A.M and Associates, GR Gupta & Associates, and V C A N & Co LLP as its statutory, secretarial, and internal auditors.
Avience Biomedicals Limited held its 7th AGM on September 30, 2026. Shareholders approved borrowing limits up to ₹100 Crore and the appointment of new statutory auditors.
Avience Biomedicals Limited has scheduled its 7th Annual General Meeting for September 30, 2026. The company also announced book closure dates for the AGM.
The company informed shareholders about accessing the 7th AGM Notice and Annual Report via web links and requested KYC updates for those with unregistered emails.
Avience Biomedicals filed notice of its 7th AGM, set for September 30, 2026, with its FY 2025-26 Annual Report. No monetary transaction is disclosed.
Avience Biomedicals Limited has appointed M/s. G.R. Gupta and Associates as the new Secretarial Auditor of the company for a term of 60 months.
Avience Biomedicals Ltd reported revenue from operations of ₹25.7 Cr (+4.9% YoY) and net profit of ₹4.2 Cr (-2.3% YoY) for H2 FY26.
Avience Biomedicals Limited informed the exchange about the non-applicability of Corporate Governance compliance requirements for the quarter ended June 30, 2026.
Avience Biomedicals reported FY26 revenue of ₹52.51 Cr (up 16%) with EBITDA margins improving to 28.45%. Strategy focuses on shifting from trading to in-house manufacturing and scaling exports.
Avience Biomedicals Limited reports 16% FY26 revenue growth with EBITDA margins expanding to 28.45%. Strategy focuses on capacity expansion via a new ₹30.18 Cr automated facility and increasing CDSCO product approvals.
Avience Biomedicals approved its audited standalone and consolidated financial results for FY26. The board also noted non-applicability of certain SEBI corporate governance and fund utilization disclosures.